ChromaDex (CDXC) is Appealing the Elysium Health Ruling - Ladenburg Thalmann
Tweet Send to a Friend
Ladenburg Thalmann analyst Jeffrey Cohen reiterated a Buy rating and $12.00 price target on ChromaDex (NASDAQ: CDXC) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
